The fluoroquinolone antibacterials: past, present and future perspectives

Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Safety 1999, 21, in press.

Lode, 1999, Potential interactions of the extended-spectrum fluoroquinolones with the CNS, Drug Safety, 21, 123, 10.2165/00002018-199921020-00005

Tillotson, 1999, Structure-activity-function evaluation of the fluoroquinolones, 2, 91

Chu DTW, Shen LL. Quinolone synthetic antibacterial agents. In: Hunter PA, Derby GK, Russell NJ (Eds.), Fifty years of antimicrobials: past perspectives and future trends. Society for General Microbiology, Symposium 53, CUP, 1995, p. 111-37.

Lescher, 1962, 1-8 naphthyridine derivatives. A new class of chemotherapeutic agents, J. Med. Pharmaceut. Chem., 5, 1063, 10.1021/jm01240a021

Domagala, 1994, Structure-activity and structure-side-effect relationships for the quinolone antibacterials, J. Antimicrob. Chemother., 33, 685, 10.1093/jac/33.4.685

Stein, 1988, The 4-quinolone antibiotics: past, present, and future, Pharmacotherapy, 8, 301, 10.1002/j.1875-9114.1988.tb04088.x

Tillotson, 1996, Quinolones: structure-activity relationships and future predictions, J. Med. Microbiol., 44, 320, 10.1099/00222615-44-5-320

Radl, 1990, Structure-activity relationships in DNA gyrase inhibitors, Pharmacol. Ther., 48, 1, 10.1016/0163-7258(90)90014-S

Hong CY, Kim YK, Nam D-H et al. SB-265805 (LB20304a): structure-activity relationship of the oxime-derivatized pyrrolidine. The importance of the oximinoalkyl group on in vitro antibacterial activity and pharmacokinetics. In: Proceedings of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998: Poster F-095.

Hong CY, Kim YK, Jang JH, Kim M-Y. SB-265805 (LB20304a): the synergistic effect of the methyloxime and aminomethyl groups of the C7-pyrrolidine on in vitro activity. In: Proceedings of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998: Poster F-096.

Spangler, 1993, Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci, Eur. J. Clin. Microbiol. Infect. Dis., 12, 965, 10.1007/BF01992176

Jacobs, 1995, Antibiotic-resistant pneumococci, Rev. Med. Microbiol., 6, 77, 10.1097/00013542-199504000-00001

Klugman, 1990, Pneumococcal resistance to antibiotics, Clin. Microbiol. Rev., 3, 171, 10.1128/CMR.3.2.171

Felmingham, 1985, Comparative in vitro studies with 4-quinolone antimicrobials, Drugs Exp. Clin. Res., 11, 317

Grüneberg, 1988, The comparative in-vitro activity of ofloxacin, J. Antimicrob. Chemother., 22, 9, 10.1093/jac/22.Supplement_C.9

Ridgway, 1985, The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae, Drugs Exp. Clin. Res., 11, 259

Bauernfeind, 1997, Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin, J. Antimicrob. Chemother., 40, 639, 10.1093/jac/40.5.639

Felmingham, 1999, In vitro activity of moxifloxacin (BAY 12-8039), a novel 8-methoxyquinolone, compared with ofloxacin and other antibiotics, 2, 27

Hoellman, 1999, Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents, J. Antimicrob. Chemother., 43, 645, 10.1093/jac/43.5.645

Visalli, 1997, Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral β-lactams, Antimicrob. Agents Chemother., 41, 2786, 10.1128/AAC.41.12.2786

Ednie, 1997, Comparative activities of clinafloxacin against gram-positive and -negative bacteria, Antimicrob. Agents Chemother., 42, 1269, 10.1128/AAC.42.5.1269

Felmingham D, Robbins M, Dencer C, Salman H, Mathias I, Ridgway G. In vitro activity of gemifloxacin against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila and Chlamydia spp. In: Proceedings of 21st International Congress of Chemotherapy, Birmingham, UK, 1999: Poster P-408.

Moore T, Niconovich N, Coleman K. SB-265805 (LB20304a): in vitro antibacterial activity against the common respiratory tract pathogens Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. In: Proceedings of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998: Poster F-098.

Nakane, 1995, In vitro antibacterial activity of DU-6859a, a new fluoroquinolone, Antimicrob. Agents Chemother., 39, 2822, 10.1128/AAC.39.12.2822

Kim M-Y, Paek K-S, Choo Y-S. SB-265805 (LB20304a): in vitro antibacterial activity against respiratory tract pathogens. In: Proceedings of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998: Poster F-093.

Cormican, 1997, Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone, Antimicrob. Agents Chemother., 41, 204, 10.1128/AAC.41.1.204

Woodcock, 1997, In vitro activity of BAY 12-8039, a new fluoroquinolone, Antimicrob. Agents Chemother., 41, 101, 10.1128/AAC.41.1.101

Paek K-S, Kim M-Y, Choo YS. SB-265805 (LB20304a): in vitro antibacterial activity and spectrum. In: Proceedings of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998: Poster F-092.

Fung-Tomc J, Gradelski E, Bonner D. Killing rates of streptococci and related organisms by fluoroquinolones. In: Proceedings of 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999: Poster 2329.

Morrissey I, George J. The bactericidal activity of gemifloxacin and other fluoroquinolones against Streptococcus pneumoniae. In: Proceedings of 21st International Conference of Chemotherapy, Birmingham, UK, 1999: Poster 487.

Visalli, 1996, MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci, Antimicrob. Agents Chemother., 40, 362, 10.1128/AAC.40.2.362

Ho, 1999, Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong, Antimicrob. Agents Chemother., 43, 1310, 10.1128/AAC.43.5.1310

Chen, 1999, Decreased susceptibility of Streptococcus pneumoniae in Canada. Canadian bacterial surveillance network, New Engl. J. Med., 341, 233, 10.1056/NEJM199907223410403

Jones, 1999, Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains, Antimicrob. Agents Chemother., 43, 421, 10.1128/AAC.43.2.421

Piddock, 1998, Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract, Antimicrob. Agents Chemother., 42, 2956, 10.1128/AAC.42.11.2956

Schmitz, 1998, Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus, J. Antimicrob. Chemother., 41, 481, 10.1093/jac/41.4.481

Pestova, 1999, Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones, Antimicrob. Agents Chemother., 43, 2000, 10.1128/AAC.43.8.2000

Durham, 1999, Preferred targets of moxifloxacin in Staphylococcus aureus, 2, 63

Heessen, 1984, In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis, Antimicrob. Agents Chemother., 25, 123, 10.1128/AAC.25.1.123

Ridgway, 1984, The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro, Eur. J. Clin. Microbiol., 3, 344, 10.1007/BF01977491

Deforges, 1986, Antibacterial activity in vitro of 10 quinolones against 20 strains of Legionella pneumophila, Pathol. Biol. (Paris), 34, 631

Roblin, 1997, In vitro activity of trovafloxacin against Chlamydia pneumoniae, Antimicrob. Agents Chemother., 41, 2033, 10.1128/AAC.41.9.2033

Jones, 1997, Susceptibility of Chlamydia trachomatis to trovafloxacin, J. Antimicrob. Chemother., 39, 63, 10.1093/jac/39.suppl_2.63

Dubois, 1999, In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin against Legionella spp., Diagn. Microbiol. Infect. Dis., 33, 261, 10.1016/S0732-8893(98)00150-3

Wise, 1997, The activity of methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones, J. Antimicrob. Chemother., 39, 447, 10.1093/jac/39.4.447

Hannan P, Woodnutt G. SB-265805 (LB203304a): susceptibility of human Mycoplasmas in vitro. In: Proceedings of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998: Poster F-101.

Ridgway GL, Salman H, Clark S, Mathias I, Felmingham D. SB-265805 (LB20304a): comparative in vitro activity against Legionella pneumophila and Chlamydia spp. In: Proceedings of 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998: Poster F-097.

Deguchi, 1997, Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins, Antimicrob. Agents Chemother., 41, 2544, 10.1128/AAC.41.11.2544

Brisse, 1999, Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins, Antimicrob. Agents Chemother., 43, 2051, 10.1128/AAC.43.8.2051

Visalli, 1997, Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods, Antimicrob. Agents Chemother., 41, 1475, 10.1128/AAC.41.7.1475

Kitamura, 1995, Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 39, 1467, 10.1128/AAC.39.7.1467

Davies TA, Hoellman D, Jacobs MR, Appelbaum PC. Activity of gemifloxacin (SB-265805) compared with other quinolones against quinolone-resistant Haemophilus influenzae. In: Proceedings of 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999: Poster 1499.

Appelbaum, 1995, Quinolone activity against anaerobes: microbiological aspects, Drugs, 49, 76, 10.2165/00003495-199500492-00012

Ednie, 1998, Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms, Antimicrob. Agents Chemother., 42, 2459, 10.1128/AAC.42.9.2459

Goldstein, 1999, In vitro activity of gemifloxacin (SB 265805) against anaerobes, Antimicrob. Agents Chemother., 43, 2231, 10.1128/AAC.43.9.2231

MacGowan, 1997, Bay 12-8039, a new methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria, J. Antimicrob. Chemother., 40, 503, 10.1093/jac/40.4.503

Marco, 1997, Antimicrobial activity of LB 20304, a fluoronaphthyridone, tested against anaerobic bacteria, J. Antimicrob. Chemother., 40, 605, 10.1093/jac/40.4.605

Spencer, 1998, The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease, J. Antimicrob. Chemother., 41, 21, 10.1093/jac/41.suppl_3.21